AzTrials
AzTrials

Knee OsteoarthritisNCT05548712

The Effect of PEMF for Patients With Knee OA

A study testing Pulse Electromagnetic Field in people with Knee Osteoarthritis and Knee Pain Chronic, run by Chinese University of Hong Kong at 1 site in Hong Kong.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Health care costs are increasing alarmingly, which will impose an overwhelming economic burden to an aging society like that of Hong Kong. For example, degenerative musculoskeletal disorders such as osteoarthritis (OA) present a grand challenge with its high prevalence (>40% in the elderly suffered from knee OA). Read more about this study

Who is it for?
Ages 50 years and olderHealthy volunteers can take part
Conditions the study is for
Knee Osteoarthritis, Knee Pain Chronic
What is being tested?
Pulse Electromagnetic Field
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteHong Kong
Study dates
5 May 2022to 15 Sep 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age 50 or above
  • knee OA with Kellgren-Lawrence grade 2-4 by X-ray
  • Sedentary lifestyle (Tegner activity level ≤ 3)
  • No acute knee injuries in past 12 months
  • No muscle strain in past 12 months
  • No degenerative joint diseases in other joints except the involved knee

Who cannot join

  • Age smaller than 50 years old
  • Experienced any concomitant bone fracture, ACL injury, major meniscus injury
  • Any rheumatological diseases
  • Metal implants that would cause interference on MRI
  • Previous contralateral knee injury
  • Recent knee injections (prior 3 months)
  • Physical inability to undertake testing procedures
  • Pregnancy or possibility of pregnancy

Trial locations and contacts

1 site in 1 country.

Michael Tim-Yun Ong contact

26364171

michael.ong@cuhk.edu.hk

Hong Kong1 site, 1 recruiting
  • The Chinese University of Hong Kong

    Hong Kong

    Michael Tim-Yun Ong, 26364171, michael.ong@cuhk.edu.hk

    Recruiting

Other trials in Hong Kong

About this study

Official title: A Double-Blinded, Randomized-Control-Trial to Investigate the Effect of Pulsed Electromagnetic Field (PEMF) for Patients With Knee Osteoarthritis

Health care costs are increasing alarmingly, which will impose an overwhelming economic burden to an aging society like that of Hong Kong. For example, degenerative musculoskeletal disorders such as osteoarthritis (OA) present a grand challenge with its high prevalence (>40% in the elderly suffered from knee OA). OA is a debilitating progressive disease with typical symptoms such as acute pain causing loss of mobility Currently there is no cure for OA. Pharmacological treatment and new regenerative technologies such as stem cell therapy are actively being developed, but most of these options are very expensive per se, and side effects are not uncommon. Costeffectiveness is also a major consideration for devising new therapeutic modalities for OA.

There are emerging evidences showing that pulsed electromagnetic field (PEMF) can modulae mitochondrial activities for muscle gain. PEMF exposure on top of regular exercise training may promote muscle regeneration and tissue healing.

Read more

This study aims to conduct a double-blinded, randomized controlled trial to investigate the effect of PEMF treatment on knee pain in patients with knee OA. We hypothesize that PEMF treatment is effective to relief in pain and improve knee function in Knee OA subjects.

Based on the aim of this study, older adult patients (aged 50 or above) with knee OA with Kellgren-Lawrence grade 2-4 by X-ray, have sedentary lifestyle (Tegner activity level less or equal to 3), no acute knee injuries in past 12 months, no muscle strain in past 12 months and not degenerative joint disease in other joints except the involved knee.

To estimate the improvement of patients, isometric quadricep muscle strength, posture assessment, serum myokine level, serum vitamin D level and selfreported outcome with questionnaires will be performed.

Being tested
Pulse Electromagnetic Field, Sham Pulse Electromagnetic Field
Keywords
Pulse electromagnetic field, PEMF, Knee Osteoarthritis, Knee OA, Knee pain
Medical subject headings
Osteoarthritis, Knee

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pulse Electromagnetic FieldDevice

    Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.

  • Sham Pulse Electromagnetic FieldDevice

    Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.

Study groups in NCT05548712
Study groupRoleWhat they receive
Treatment groupExperimentalNot described
Receives: Device: Pulse Electromagnetic Field
Sham groupSham comparatorNot described
Receives: Device: Sham Pulse Electromagnetic Field

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change of Peak torque of Isometric muscle strength

    The peak torque in kgf will be recorded with in 2 trials in the 5 seconds isometric muscle strength test.

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

Secondary outcomes (11)
  1. International Physical Activity Questionnaire

    Consists of four items recording the subject's time of spending on physical activities during the past 7 days with a validated Chinese version of the quantitative physical activity questionnaire, and the physical activity level will be evaluated by Metabolic Equivalent of task(MET) per minute and classified as physical level with Low, Moderate or High.

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  2. Tegner activity score

    This is an activity level scaled from 1 (low activity) to 10 (high activity).

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  3. Short Form-36 questionnaires (SF-36)

    This is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  4. Serum myokine evaluation

    Phlebotomy (5ml) will be performed on the day before PEMF treatment, at 4- and 8- weeks after commencement of treatment, and at 8 months after the commencement of intervention. The serum will be prepared by centrifugation and kept in a -80o freezer until use. Quantitative analysis for myokines and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml. These include Brain-derived neurotrophic factor (BDNF), Fibroblast growth factor-21 (FGF-21), Interleukin-6 (IL-6), IL-15, Irisin, Myostatin (MSTN)/GDF8, Insulin-like growth factor 1 (IGF-1), FGF-2, IL-8, Follistatin, Musclin, Myonectin, Decorin, Meteorinlike, Osteopontin, Secreted protein acidic and rich in cysteine (SPARC), Klotho, Procollagen type III Nterminal peptide (P3NP), and C- terminal of troponin T1 (TNNT1).

    Measured: pre PEMF treatment, 3-months, 6-months, and 12-months after the commencement of PEMF

  5. The speed and rate of force development in 6 repetitions in chair stand test

    The rate of force development will be determined as the mean slope of the rising force of the first force peak of each of the 2nd to the 6th repetition in the interval of 30-70% exerted peak force. Results are reported as the mean of the two fastest approved trials in body weight per second (BW/s).

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  6. Change of centre of pressure with the position of double leg squat

    The centre of pressure excursion range in the anterior-posterior direction in mm will be recored.

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  7. Change of centre of pressure with the position of static postural codition

    The centre of pressure excursion range in the anterior-posterior direction in mm will be recored.

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  8. Change of centre of pressure with the position of dynamic postural codition

    The centre of pressure excursion range in the anterior-posterior direction in mm will be recored.

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  9. Serum vitamin D level and vitamin D metabolites evaluation

    Blood samples will be taken under non-fasting conditions. Serum / plasma obtained will be immediately stored at -80°C until analysis. Serum 25(OH) Vit-D assay: Serum 25(OH)Vit-D levels will be measured by commercial 25(OH) Vitamin D ELISA kit (Abcam ab213966) according to the manufacturer's instruction, providing the quantitative determination of 25(OH) Vitamin D3 and 25(OH) Vitamin D2. Sensitivity: 1.98 ng/ml (Range: 0.5 ng/ml - 1010 ng/ml).

    Measured: pre PEMF treatment, 3-months, 6-months, and 12-months after the commencement of PEMF

  10. Visual Analogue Scale

    The subjective measurement for chronic and acute pain will be recorded by the Visual Analogue Scale (VAS). VAS consists of a 10-cm line which represents the continuum between "painless" and "worst pain from 0 cm to 10 cm. The subject will be asked to draw a mark of it before and after each PEMF treatment session.

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  11. Change of the scoring of Knee injury and Osteoarthritis Outcome Score

    Consist of 42 items with 5 subscapes: pain, other symptoms, function in daily living (ADL), function in sport and recreation (Sport/Rec), and knee-related quality of life (QOL) from 0% to 100% where higher score indicate a better outcome in each subscape.

    Measured: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2022
  2. Study start5 May 2022
  3. Primary completion15 Sep 2024 (estimated)
  4. Study completion15 Sep 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be assigned into either treatment group or sham group.
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05548712
Sponsor's protocol ID
2021.491
Status last verified
Dec 2023
First submitted
12 Aug 2022
Last updated
20 Dec 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD that underlie results in a publication.

Questions about this trial

What is this clinical trial studying?

A study testing Pulse Electromagnetic Field in people with Knee Osteoarthritis and Knee Pain Chronic, run by Chinese University of Hong Kong at 1 site in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Michael Tim-Yun Ong (26364171, michael.ong@cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change of Peak torque of Isometric muscle strength (time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in